


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the current application.

Listing of Claims

Claim 1 (currently amended). A compound of a formula I:



I

or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein


- (a) each occurrence of Z is ~~independently~~ CH₂, CH=CH, or phenyl, and wherein each occurrence of m is independently an integer ranging from 1 to 9, ~~but when Z is phenyl then its associated m is 1;~~
- (b) G is (CH₂)_x, CH₂CH=CHCH₂, CH=CH, CH₂phenyl-CH₂, or phenyl, wherein x is 2, 3, or 4;
- (c) W¹ and W² are independently L, V, ~~or~~ C(R¹)(R²)-(CH₂)_c-C(R³)(R⁴)-(CH₂)_n-Y, ~~or~~ C(R¹)(R²)-(CH₂)_c-Y, wherein c is 1 or 2 and n is an independent integer ranging from 0 to 4;
- (d) R¹ and R² are independently CO₂H, CO₂(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl or when W¹ or W² is C(R¹)(R²)-(CH₂)_c-C(R³)(R⁴)-Y, then R¹ and R² can both be H, or R¹ and R² and the carbon to which they are both attached are taken together to form a (C₃-C₇)cycloalkyl group;
- (e) R³ and R⁴ are independently H, OH, CO₂H, CO₂(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₆)alkoxy, phenyl, benzyl, Cl, Br, CN, NO₂, or CF₃, with the proviso that when R¹ and R² are both H, then one of R³ or R⁴ is not H or R³ and R⁴ and the carbon to which they are both attached are taken together to form a (C₃-C₇)cycloalkyl group::

USSN: 10/743,952


PC20608

(f) L is $C(R^1)(R^2)-(CH_2)_n-Y$;

(g) —V is



(h)(g) Y is (C_1-C_6) alkyl, OH, COOH, CHO, COOR⁵, SO₃H,



where

- (I) R^5 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (ii) each occurrence of R^6 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and
- (iii) each occurrence of R^7 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and

provided that:

- (i) if G is $(CH_2)_x$, x is 4, each occurrence of Z is CH_2 , each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ; and
- ~~(ii) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(CH_3)_2CH(CO_2CH_2CH_3)_2$, then W^2 is not the same as W^1 ;~~
- ~~(iii) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(CH_3)_2CH_2(CO_2CH_2CH_3)$, then W^2 is not the same as W^1 ;~~
- ~~(iv) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-COCH_2C(CH_3)_2CH_2CO_2H$, then W^2 is not the same as W^1 ;~~
- ~~(v)(ii) if G is $(CH_2)_x$, x is 4, each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 ;~~
- ~~(vi) if G is $CH=CH$, each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-C(CH_3)_2CH_2(CO_2H)$, then W^2 is not the same as W^1 ; and~~

USSN: 10/743,952

PC20608

~~(vii) if G is phenyl, each occurrence of Z is CH₂, each occurrence of m is 1, and W¹ is C(phenyl)₂CO₂H, then W² is not the same as W¹.~~

Claim 2 (currently amended). The compound of claim 1, wherein:

- (a) W¹ and W² are ~~independently both~~ L, V, or C(R¹)(R²)-(CH₂)_e-V where e is 1 or 2; and
- (b) ~~R¹ or R² are independently~~ (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl.

Claims 3 (original). The compound of claim 1, wherein W¹ is L.

Claim 4 (canceled).


Claim 5 (original). The compound of claim 1, wherein W¹ is C(R¹)(R²)-(CH₂)_e-C(R³)(R⁴)-(CH₂)_n-Y.

Claim 6 (canceled).

Claim 7 (original). The compound of claim 1, wherein W¹ and W² are independent L groups.

Claim 8 (original). The compound of claim 7, wherein each occurrence of Y is independently (CH₂)_nOH, (CH₂)_nCOOR⁵, or (CH₂)_nCOOH.

Claim 9 (currently amended). A compound of the formula Ia:




or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein


USSN: 10/743,952

PC20608

- (a) each occurrence of Z is independently CH_2 or $\text{CH}=\text{CH}$, wherein each occurrence of m is independently an integer ranging from 1 to 9;
- (b) G is $(\text{CH}_2)_x$, $\text{CH}_2\text{CH}=\text{CHCH}_2$, or $\text{CH}=\text{CH}$, where x is 2, 3, or 4;
- (c) W^1 and W^2 are independently L, V, or $\text{C}(\text{R}^1)(\text{R}^2)(\text{CH}_2)_e\text{V}$, where e is 1 or 2;
- (d) each occurrence of R^1 and R^2 is independently CO_2H , $\text{CO}_2(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_2\text{-C}_6)\text{alkenyl}$, $(\text{C}_2\text{-C}_6)\text{alkynyl}$, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(\text{C}_3\text{-C}_7)\text{cycloalkyl}$ group;
- (e) L is $\text{C}(\text{R}^1)(\text{R}^2)(\text{CH}_2)_n\text{Y}$, where n is an independent integer ranging from 0 to 4;
- (f) V is




- (g) each occurrence of Y is independently $(\text{C}_1\text{-C}_6)\text{alkyl}$, OH, COOH , CHO, $(\text{CH}_2)_n\text{COOR}^3$, SO_3H ,



USSN: 10/743,952

PC20608



where

- (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and

provided that:


- (i) if x is 4, each occurrence of Z is CH_2 , each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ;
- (ii) if x is 4, each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 .

Claims 10-12 (canceled).

Claim 13 (original). The compound of claim 9, wherein W^1 and W^2 are independent L groups.


Claim 14 (original). The compound of claim 13, wherein each occurrence of Y is independently OH, $COOR^3$, or $COOH$.

Claim 15 (currently amended). A compound of the formula Ib


Ib


or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

- (a) each occurrence of m is independently an integer ranging from 1 to 9;
- (b) x is 2, 3, or 4;
- (c) n is an independent integer ranging from 0 to 4;
- (d) each occurrence of R^1 and R^2 is independently CO_2H , $CO_2(C_1-C_6)alkyl$, $(C_1-C_6)alkyl$, $(C_2-C_6)alkenyl$, $(C_2-C_6)alkynyl$, phenyl, benzyl, or R^1 and R^2 and the carbon to which they are both attached are taken together to form a $(C_3-C_7)cycloalkyl$ group;
- (e) each occurrence of R^{11} and R^{12} is independently H , CO_2H , $CO_2(C_1-C_6)alkyl$, $(C_1-C_6)alkyl$, $(C_2-C_6)alkenyl$, $(C_2-C_6)alkynyl$, phenyl, benzyl, or R^{11} and R^{12} and the carbon to which they are both attached are taken together to form a $(C_3-C_7)cycloalkyl$ group;
- (f) each occurrence of Y is independently $(C_1-C_6)alkyl$, OH , $COOH$, CHO , $COOR^3$, SO_3H ,



USSN: 10/743,952

PC20608



where

- (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

provided that:

- (i) if x is 4 each occurrence of m is 4, and W^1 is $-\text{CH}(\text{CH}_3)\text{CO}_2\text{H}$, then W^2 is not the same as W^1 ;
- (ii) if x is 4 each occurrence of m is 2, and W^1 is $-\text{C}(\text{phenyl})_2\text{CH}_2\text{CO}_2\text{H}$, then W^2 is not the same as W^1 .

Claim 16 (original). The compound of claim 15, wherein each occurrence of Y is independently OH, COOR^3 , or COOH .

Claim 17 (original). The compound of claim 16, wherein each R^1 or R^2 is the same or different (C_1-C_6) alkyl group.

Claim 18 (canceled).

Claim 19 (original). A compound according to claim 1, having the formula
5-[2-(5-hydroxy-4,4-dimethyl-pentyloxy)-ethoxy]-2,2-dimethyl-pentan-1-ol or
4-[3-(3,3-Dimethyl-4-oxo-butoxy)-propoxy]-2,2-dimethyl-butyric acid.

Claims 20-33 (canceled).

USSN: 10/743,952

PC20608

Claim 34 (currently amended). A pharmaceutical composition comprising a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30 and a pharmaceutically acceptable vehicle, excipient, or diluent.

Claim 35 (original). A pharmaceutical composition comprising the following compound: 6-(5,5-Dimethyl-6-hydroxy-hexane-1-sulfinyl)-2,2-dimethyl-hexan-1-ol or pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof and a pharmaceutically acceptable vehicle, excipient, or diluent.

Claim 36 (currently amended). A method for treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

Claim 37 (currently amended). A method for treating or preventing a dyslipidemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

Claim 38 (currently amended). A method for treating or preventing a dyslipoproteinemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

Claim 39 (currently amended). A method for treating or preventing a disorder of glucose metabolism in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

USSN: 10/743,952

PC20608

Claim 40 (currently amended). A method for treating or preventing Alzheimer's Disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

Claim 41 (currently amended). A method for treating or preventing Syndrome X or Metabolic Syndrome in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

Claim 42 (currently amended). A method for treating or preventing septicemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

Claim 43 (currently amended). A method for treating or preventing a thrombotic disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

Claim 44 (currently amended). A method for treating or preventing a peroxisome proliferator activated receptor associated disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

Claim 45 (currently amended). A method for treating or preventing obesity in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

Claim 46 (currently amended). A method for treating or preventing pancreatitis in a patient, comprising administering to a patient in need of such treatment

USSN: 10/743,952

PC20608

or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18,
20, 21, 26, or 30.

Claim 47 (currently amended). A method for treating or preventing hypertension in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18,
20, 21, 26, or 30.

Claim 48 (currently amended). A method for treating or preventing renal disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20,
21, 26, or 30.

Claim 49 (currently amended). A method for treating or preventing cancer in a patient, comprising administering to a patient in claim 1, 9, or 15, 18, 20, 21, 26, or
30.

Claim 50 (currently amended). A method for treating or preventing inflammation in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18,
20, 21, 26, or 30.

Claim 51 (currently amended). A method for treating or preventing impotence in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, 18, 20,
21, 26, or 30.

Claim 52 (currently amended). A method for treating or preventing a neurodegenerative disease or disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 9, or 15, 18, 20, 21, 26, or 30.

USSN: 10/743,952

PC20608

Claim 53 (currently amended). A method of inhibiting hepatic fatty acid synthesis in a patient, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of claim 1, 9, or 15, ~~18, 20, 21, 26, or 30~~.

Claim 54 (currently amended). A method of inhibiting sterol synthesis in a patient, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of claim 1, 9, or 15, ~~18, 20, 21, 26, or 30~~.

Claim 55 (currently amended). A method of treating or preventing metabolic syndrome disorders in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 9, or 15, ~~18, 20, 21, 26, or 30~~.

Claim 56 (currently amended). A method of treating or preventing a disease or disorder that is capable of being treated or prevented by increasing HDL levels, which comprises administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, ~~18, 20, 21, 26, or 30~~.

Claim 57 (currently amended). A method of treating or preventing a disease or disorder that is capable of being treated or prevented by lowering LDL levels, which comprises administering to such patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, or 15, ~~18, 20, 21, 26, or 30~~.